- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03698825
TEW-7197 With Paclitaxel for the Treatment of Metastatic Gastric Cancer
An Open-label, Multicenter Phase Ib/2a Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In the dose escalation step (phase 1b), 3 subjects are registered for each dose step, and the DLT is evaluated by administering the investigational product for 1 cycle (28 days). However, for reasons other than toxicity related to the test drug, the patient was given a combination of Paclitaxel and TEW-7197 (Vactosertib) during the DLT evaluation period during the first cycle of the planned TEW-7197.
If more than 80% of the administered dose of (Vactosertib) is not administered, the patient will be considered unevaluable for DLT and another patient will be enrolled. At the end of one cycle of each cohort, the SMC decides whether to proceed to the next cohort. After completing the DLT evaluation of the final phase 1 cohort, the recommended dose to proceed in the dose expansion phase (Phase 2a) is determined. For subjects who have completed one cycle (DLT evaluation period), administer the investigational drug at the same dose until disease progression or unacceptable toxicity occurs. Tumor imaging (CT or MRI) for tumor evaluation is performed after screening and C1D1. Assessment every 6 weeks (±2 weeks) and at the end of treatment (EOT/DC). As efficacy evaluation items, PFS, OS, ORR, and DCR are evaluated according to RECIST 1.1, and the amount of change in the biomarker is confirmed.
In the dose expansion phase (phase 2a), 50 patients will be enrolled at the dose determined in the dose escalation phase. Tumor imaging (CT or MRI) for tumor evaluation is evaluated every 6 weeks (±2 weeks) after screening and C1D1, and at the end of treatment (EOT/DC). As validity evaluation items, PFS, OS, ORR, and DCR according to RECIST 1.1 are evaluated, and the amount of change in the biomarker is confirmed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Anyang-si, Korea, Republic of
- Hallym University Medical Center
-
Hwasun, Korea, Republic of
- Hwasun Chunnam university hospital
-
Seoul, Korea, Republic of
- Chung-Ang University Hospital
-
Seoul, Korea, Republic of
- Gangnam Severance
-
Seoul, Korea, Republic of
- Gangbuk Samsung Medical Center
-
Seoul, Korea, Republic of
- Shinchon Severance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women over 19 years of age
- Patients diagnosed with histologically or cytologically metastatic gastric cancer
- Patients corresponding to ECOG Performance Status 0
The 5-Fluorouracil family (5-Fluorouracil) is the primary treatment for metastatic gastric cancer.
Patients who received additional Trastuzumab coalescing therapy for Cisplatin (Oxaliplatin) and Platinum (Oxaliplatin) or HER2-positive.
- Patients with evalable lesions according to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
Patients with the following laboratory test values during screening:
- Bilirubin is not more than 1.5 times the upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) not more than 3 times ULN (if liver metastasis, not more than 5 times ULN)
- Serum cretin is not more than 1.5 times the ULN
- Absolute neutrophil count (ANC)가 1,000 cells/µL 이상
- Platelet count is over 80,000/µL
- Hemoglobin count 가 9.0 g/dL 이상
- Patients who voluntarily agreed to participate in the clinical trial after hearing the explanation of this clinical trial.
Exclusion Criteria:
- Patients with unresolved chronic toxicity of CTC grade 2 or higher in previous chemotherapy
- Patients who have received chemotherapy or chemotherapy within two weeks prior to screening
- Patients who have undergone major surgery or radiation treatment within four weeks prior to screening
- Patients who have received medication for other clinical trials before screening and have less than 5 times the period of this half-life. Patients who are less than two weeks from the date of final administration if the half-life of the previous clinical trial drug is not clear.
- Patients previously treated with paclitaxel
- Patients who previously received treatment targeting the TGF-£ signaling pathway
- Patients who cannot take tablets
- Patients who are neurologically unstable due to overall metastasis in the central nervous system or who have increased the amount of steroid to alleviate the central nervous system signs within two weeks before screening.
If another type of tumor is present, or within three years prior to screening, another tumor is present.
diagnosed patients (except for single basal cell carcinoma, thyroid cancer and cervical cancer-insitu)
- Patients with a history of congestive heart failure or myocardial infarction that is not controlled by medication
- Pregnant women who are positive for pregnancy test results in this clinical trial and contraception by themselves and their partners during the safety follow-up period after treatment (e.g., infertility surgery, intrauterine, oral contraceptives, liver wall contraception, and other hormone delivery systems, creams, jellies, etc.)
- Patients with evidence of cirrhosis above Child-Pugh B or C. For HBV or HCV-linked chronic hepatitis or cirrhosis Child-Pugh A, it can be registered for clinical trials if the liver function is reliably maintained through medication.
- Other patients who are deemed unfit to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation of TEW-7197
TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
|
TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 4 weeks
|
To define the MTD and determine RP2D
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events assessed by NCI CTCAE v5.0
Time Frame: from screening through study completion (up to 28 days after the last dose of TEW-7197), an average of 1 year.
|
To evaluate safety profile of TEW-7197 with regards to frequency, type, grade, and seriousness, and causality of treatment-related clinical and laboratory adverse events including, but not limited to, AST, ALT, total bilirubin, serum creatinine, etc.
|
from screening through study completion (up to 28 days after the last dose of TEW-7197), an average of 1 year.
|
Overall survival
Time Frame: every 2 cycles (8 weeks) and end-of-treatment (EOT) time point. EOT is defined as within 7 days from the last dose of study medication by the protocol.
|
Overall survival (months, median) defined by RECIST 1.1
|
every 2 cycles (8 weeks) and end-of-treatment (EOT) time point. EOT is defined as within 7 days from the last dose of study medication by the protocol.
|
Objective response
Time Frame: every 2 cycles (8 weeks) and end-of-treatment (EOT) time point. EOT is defined as within 7 days from the last dose of study medication by the protocol.
|
Objective response rate (%) defined by RECIST 1.1
|
every 2 cycles (8 weeks) and end-of-treatment (EOT) time point. EOT is defined as within 7 days from the last dose of study medication by the protocol.
|
pharmacokinetics of TEW-7197
Time Frame: At cycle 1 (each cycle is 28 days)
|
Peak Plasma Concentration (Cmax) of TEW-7197 Area under the plasma concentration versus time curve (AUC) of TEW-7197
|
At cycle 1 (each cycle is 28 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
pSMAD as a pharmacodynamic marker
Time Frame: At baseline and cycle 1 (each cycle is 28 days)
|
pSMAD in peripheral blood mononuclear cell determined by immunohistochemistry
|
At baseline and cycle 1 (each cycle is 28 days)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MP-GC-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Gastric Cancer
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastric Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Gastric Cancer | Unresectable Esophageal Cancer | Metastatic Esophageal Carcinoma | Metastatic Gastric... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
Royal Marsden NHS Foundation TrustRecruitingMetastatic Gastric Cancer | Metastatic Esophageal CancerUnited Kingdom
-
Erasmus Medical CenterSanofiWithdrawnMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerNetherlands
-
Amsterdam UMC, location VUmcAstraZenecaRecruitingBreast Cancer | Gastric Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric CancerNetherlands
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedMetastatic Breast Cancer | Metastatic Gastric CancerChina
-
Huashan HospitalSeattle Integrative Cancer CenterUnknownMetastatic Gastric Cancer | Locally Advanced Gastric CancerChina, United States
-
Astellas Pharma Global Development, Inc.AvailableMetastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma CancerUnited States
-
Shanghai Miracogen Inc.RecruitingAdvanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction CancerUnited States
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
Clinical Trials on TEW-7197
-
MedPacto, Inc.CompletedMyelodysplastic SyndromesUnited States
-
MedPacto, Inc.CompletedHealthy VolunteersKorea, Republic of
-
Joon Oh ParkRecruitingMetastatic Pancreatic CancerKorea, Republic of
-
MedPacto, Inc.National OncoVentureCompletedAdvanced Stage Solid TumorsUnited States
-
MedPacto, Inc.AstraZenecaUnknownNon-Small Cell Lung Cancer MetastaticKorea, Republic of
-
MedPacto, Inc.AstraZenecaNot yet recruitingUrothelial Carcinoma Recurrent | Advanced Urothelial CarcinomaUnited States
-
Samsung Medical CenterRecruitingPancreas CancerKorea, Republic of
-
Weill Medical College of Cornell UniversityRecruitingMyeloproliferative NeoplasmUnited States
-
MedPacto, Inc.RecruitingOsteosarcomaUnited States, Korea, Republic of